NCT03530917View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

May 15, 2019

Study Completion Date

May 15, 2019

Conditions
Healthy Participants
Interventions
DRUG

RO7020531

4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.

DRUG

Placebo

Placebo hard capsules will be administered orally as per the dosing schedules described above.

Trial Locations (1)

Unknown

Prince of Wales Hospital, Shatin, New Territories

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03530917 - A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants. | Biotech Hunter | Biotech Hunter